Halozyme Therapeutics HALO Return on equity

Return on equity at other companies

West Pharmaceutical ServicesWST

19.1%+1.4pp

AptarGroupATR

15%-0.2pp

Opko HealthOPK

-5.9%-2.1pp

Amneal Pharmaceuticals, Inc.AMRX

-52.8%-12.7pp

LQD

Liquidia CorporationLQDA

-181%+57.4pp

Ionis PharmaceuticalsIONS

-105.5%+336pp

FAQ

What is Halozyme Therapeutics's return on equity?

Halozyme Therapeutics (HALO) reported return on equity of 124.5% in Q3 2025.

How has Halozyme Therapeutics's return on equity changed year-over-year?

Halozyme Therapeutics's return on equity increased by 11.3% year-over-year, from 111.8% to 124.5%.

What is the long-term trend for Halozyme Therapeutics's return on equity?

Over 4 years (2020 to 2024), Halozyme Therapeutics's return on equity has grown at a 16.9% compound annual growth rate (CAGR), from 106.3% to 198.4%.

What does return on equity mean?

Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.